Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Could you further elaborate on your plans to modify the assay configuration and surface chemistry? What are the specific issues you're currently facing that these changes would address? A: The key aspect of the assay involves driving the specific binding of our affinity reagents to proteins with an epitope of interest and differentiating non-specific binding. Factors like how probes are labeled with a fluorophore and surface chemistry can influence this. Optimizing these elements will enhance the assay's performance. (Answered by Unidentified_4)
Q: Does the plan changes to the assay configuration or the surface chemistry change how you're thinking about the cost structure of the platform or consumables? A: The changes have no negative impact on cost and may even positively affect consumable costs. We anticipate that our pricing remains roughly correct, with an instrument deal around $1 million and sample costs starting at a few thousand dollars per sample. (Answered by Unidentified_3)
Q: Shouldn't surface chemistry be uniform for all proteins? And if tau worked so well, why does that require optimization for different proteins? A: The immobilization of proteins via nanoparticles to the surface is identical across assays. However, different labeling strategies and buffers can affect non-specific binding. Optimization ensures specific binding across various proteins. (Answered by Unidentified_4)
Q: Could you review the key milestones and timing over 2025 and 2026? A: For proteoform detection, we aim to provide platform capabilities for tau-related studies in the first half of 2025 and sign a tau-related partnership. For broad-scale discovery, decoding a significant number of proteins from complex samples is a major milestone. We will share data and updates at scientific conferences. (Answered by Unidentified_3)
Q: How does your platform's performance compare to other tau protein platforms? A: Our platform uniquely measures proteoforms in high throughput and sensitivity from complex samples, revealing detailed isoform and phosphorylation patterns. This capability is crucial for understanding Alzheimer's disease progression and therapeutic responses. (Answered by Unidentified_4)
Q: Is the late 2026 launch for both the broad-scale discovery and the more targeted platform, or are those timelines different? A: The broad-scale discovery platform is set for a commercial launch in late 2026. The proteoform platform will be introduced through partnerships and collaborations, focusing initially on tau proteoforms. (Answered by Unidentified_3)
Q: Does the launch date impact your expectations for the early access program on the broad-scale side? A: The early access period, starting 6 to 9 months before the commercial launch, allows customers to see data from their samples. This period aims to generate excitement and secure orders for the instrument. (Answered by Unidentified_3)
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.